Thermal stabilization of enterovirus A 71 and production of antigenically stabilized empty capsids.

J Gen Virol

Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.

Published: August 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Enterovirus A71 (EVA71) infection can result in paralysis and may be fatal. In common with other picornaviruses, empty capsids are produced alongside infectious virions during the viral lifecycle. These empty capsids are antigenically indistinguishable from infectious virus, but at moderate temperatures they are converted to an expanded conformation. In the closely related poliovirus, native and expanded antigenic forms of particle have different long-term protective efficacies when used as vaccines. The native form provides long-lived protective immunity, while expanded capsids fail to generate immunological protection. Whether this is true for EVA71 remains to be determined. Here, we selected an antigenically stable EVA71 virus population using successive rounds of heating and passage and characterized the antigenic conversion of both virions and empty capsids. The mutations identified within the heated passaged virus were dispersed across the capsid, including at key sites associated with particle expansion. The data presented here indicate that the mutant sequence may be a useful resource to address the importance of antigenic conformation in EVA71 vaccines.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019091PMC
http://dx.doi.org/10.1099/jgv.0.001771DOI Listing

Publication Analysis

Top Keywords

empty capsids
16
capsids
5
thermal stabilization
4
stabilization enterovirus
4
enterovirus production
4
production antigenically
4
antigenically stabilized
4
empty
4
stabilized empty
4
capsids enterovirus
4

Similar Publications

Preparative choline-based anion-exchange chromatography for enrichment of full adeno-associated virus capsids.

J Chromatogr A

August 2025

Tosoh Bioscience LLC, 3604 Horizon Drive, King of Prussia, PA 19406, USA. Electronic address:

Recombinant adeno-associated virus (AAV) vectors have emerged as powerful gene delivery tools for the treatment of genetic disorders. However, the production of high-quality AAV vectors still poses significant challenges. In upstream manufacturing, AAV genome packaging typically results in a diverse pool of empty and partially filled capsids, as well as the desired functional virions.

View Article and Find Full Text PDF

Accelerated Adeno Associated Virus Upstream Process Development From High-Throughput Systems to Clinical Scale.

Biotechnol Bioeng

August 2025

BioProcess Sciences, Pharma Services, Viral Vector Services, Thermo Fisher Scientific, Plainville, Massachusetts, USA.

Adeno-associated virus (AAV) is one of the most common delivery systems used in gene therapy. Challenges in the development and manufacturing of AAVs include high cost of goods (COGs) per dose, process scalability, speed to market, and process-related impurities such as empty capsids. This article presents a streamlined approach to developing and scaling AAV upstream production process via triple transfection from bench scale to commercial volumes exceeding 1,000 L.

View Article and Find Full Text PDF

Picornavirus cell entry requires a series of capsid protein conformational changes leading to genome uncoating. For enteroviruses, receptor binding triggers the transition from a full (F) capsid to an altered (A) particle before releasing its genome and finally converting it into an empty (E) particle. In contrast, non-enteroviruses, such as Aphthovirus, Cardiovirus, or Seneca Valley virus, release their genomes by dissociating the capsid into pentamers.

View Article and Find Full Text PDF

A proof of concept study on the use of online two-dimensional SEC-UV-RPLC-MS method for the multi-attribute characterization of gene therapy products.

Anal Chim Acta

October 2025

School of Pharmaceutical Sciences, University of Geneva, CMU, Rue Michel Servet 1, 1211, Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU, Rue Michel Servet 1, 1211, Geneva, Switzerland. Electronic address:

Background: Recombinant adeno-associated virus (rAAV) vectors have emerged as a leading platform for gene therapy, supported by several FDA-approved products and numerous clinical trials. Due to their biological complexity and heterogeneity, rigorous analytical methods are essential to ensure the quality, safety, and efficacy of rAAV-based products. Critical quality attributes (CQAs) such as aggregation, full/empty capsid ratios, viral protein composition, and post-translational modifications (PTMs) must be monitored comprehensively.

View Article and Find Full Text PDF

Parvoviruses are single-stranded DNA viruses that have been modified to serve as vehicles for therapeutic transgene delivery in the form of recombinant Adeno-Associated Virus (rAAV2) vectors or rodent parvovirus-derived oncolytic agents. Infection with viruses of the Parvoviridae family induces a cellular DNA Damage Response (DDR) signal that supports virus replication. However, it remains unknown whether rAAV2 vectors or non-replicative wild-type AAV2 (wtAAV2) genomes induce cellular DDR signals, which might be deleterious to the cell.

View Article and Find Full Text PDF